Text Size

Microarray Analysis of microRNA Expression in Basal Cell Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01498250
First received: December 20, 2011
Last updated: October 15, 2012
Last verified: October 2012
History of Changes
  Purpose

Perturbations in microRNA (miRNA) expression profiles has been reported for a variety of cancers. This study will be an exploratory analysis of miRNA expression in basal cell carcinoma by miRNA expression profiling using microarrays.


Condition
Basal Cell Carcinoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Microarray Analysis of microRNA Expression in Basal Cell Carcinoma

Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention:   Samples With DNA

basal cell carcinoma and non-lesional skin


Enrollment: 7
Study Start Date: November 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
basal cell carcinoma
non-lesional skin

Detailed Description:

Perturbations in the expression profiles of microRNAs (miRNAs) have been reported for a variety of different cancers. Basal cell carcinoma (BCC) of the skin has not been systematically evaluated regarding differentially expressed miRNAs. Patients with BCC are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

  Eligibility

Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with

Basal Cell Carcinoma

Criteria

Inclusion Criteria:

  • Basal Cell Carcinoma

Exclusion Criteria:

  • Other Skin Cancer than Basal Cell Carcinoma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01498250

Locations
Germany
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Study Director: Falk G Bechara, PD Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Study Chair: Peter Altmeyer, Prof. Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Principal Investigator: Michael Sand, Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
  More Information

Publications:

Responsible Party: Michael Sand, Principal Investigator, Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT01498250     History of Changes
Other Study ID Numbers: microRNA6
Study First Received: December 20, 2011
Last Updated: October 15, 2012
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell

ClinicalTrials.gov processed this record on May 16, 2013